List view / Grid view
The ABPI has found that the UK is leading the…
The ABPI has found that the UK is leading the rest of Europe in early-stage clinical trials and makes suggestions on how the country can maintain this position.
UK politicians were warned that without a post-Brexit deal on…
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
The ABPI and EFPIA have both emphasised the need for…
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
The ABPI has responded to new guidance, intended to prepare…
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
The fund has already raised $1 billion to support clinical…
The fund has already raised $1 billion to support clinical research of novel antibiotics and intends to bring up to four new antibiotics to market by 2030.
The UK government has pledged funding of £22 billion per…
The UK government has pledged funding of £22 billion per year into R&D by 2025 in its Budget, just days after a further £46 million was invested into coronavirus research.
A written statement from the UK government has highlighted the…
A written statement from the UK government has highlighted the importance of trade co-operation with the EU, including for pharmaceuticals.
